SNDX Stock Risk & Deep Value Analysis
Syndax Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SNDX Stock
We analyzed Syndax Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SNDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SNDX Risk Analysis & Red Flags
What Could Go Wrong
The company continues to burn cash at a significant rate, and while its cash balance is $352.1M, continued negative gross margins or clinical trial failures for pipeline assets could necessitate further dilutive financing before sustainable profitability is achieved, substantially impacting shareholder value.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Increased royalty interest expense impacting operating leverage
- ⚠
Potential future dilution from the proposed 2026 Equity Incentive Plan (7.2M shares)
- ⚠
Q1 2026 revenue miss vs. analyst estimates.
Upcoming Risk Events
- 📅
Clinical trial failures or significant delays for axatilimab or other pipeline assets
- 📅
Regulatory setbacks for existing or pipeline products
- 📅
Increased competitive pressure in oncology markets
When to Reconsider
- 🚪
Failure of axatilimab Phase 2 trial or other key pipeline milestones
- 🚪
Sustained quarter-over-quarter decline in Revuforj/Niktimvo sales growth below guidance
- 🚪
Gross margin (when reported) failing to show significant improvement or deteriorating further
Unlock SNDX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Syndax Pharmaceuticals Inc (SNDX) Do?
Market Cap
$1.69B
Sector
Healthcare
Industry
Biotechnology
Employees
270
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Visit Syndax Pharmaceuticals Inc WebsiteInvestment Thesis
Syndax is an emerging oncology player with strong early commercial success for Revuforj and Niktimvo, demonstrating robust revenue growth. Its improving profitability trajectory and promising pipeline, particularly axatilimab, position it for significant market share gains in unmet oncology needs, offering substantial upside despite inherent biotech risks. Continued execution on commercialization and positive pipeline data could unlock considerable value.
Is SNDX Stock Undervalued?
Unlock the full AI analysis for SNDX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SNDX Price Targets & Strategy
12-Month Target
$45.00
Bull Case
$65.00
Bear Case
$15.00
Valuation Basis
Based on 9x forward P/S applied to estimated FY2027 revenue of $450M.
Entry Strategy
Dollar-cost average between $18-$22, utilizing any dips towards recent support levels around $18.
Exit Strategy
Consider taking initial profits at $40-$45; exit fully or re-evaluate at $65.00. Implement a stop loss if price falls below $15.00.
Portfolio Allocation
7-10% for aggressive risk tolerance due to high growth potential and inherent biotech volatility.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is SNDX Financially Healthy?
Valuation
P/E Ratio
-6.04
PEG Ratio
0.14
Price/Book
3.90
Price/Sales
11.00
Profitability
Gross Margin
95.96%
Operating Margin
-158.22%
Net Margin
-165.37%
Return on Equity
-206.62%
Revenue Growth
628.88%
EPS
$-3.30
Balance Sheet
Current Ratio
4.40
Quick Ratio
4.04
Debt/Equity
5.32
Cash & Equivalents
$352.10M
Other
Beta (Volatility)
0.43
Does SNDX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by intellectual property and the significant investment required for clinical development and regulatory approval. This offers protection for the patent life of successful drugs. Continued pipeline success and market penetration can solidify this moat, but it's inherently vulnerable to clinical failures or superior competing treatments.
Moat Erosion Risks
- •Expiration of key patents or legal challenges to IP
- •Emergence of more effective or safer competitor therapies
- •Failure of clinical trials to demonstrate significant advantage over existing treatments
SNDX Competitive Moat Analysis
Sign up to see competitive advantages
SNDX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Biotech sector often sees mixed retail sentiment, focused on clinical news)
Institutional Sentiment
Mixed (Vanguard increased holdings by 27.4% in Q4 2025; Millennium Management decreased by 95.0% in Q4 2025). No recent analyst upgrades/downgrades provided.
Insider Activity (Form 4)
No specific Form 4 filings with transaction details from company insiders (officers/directors) are provided in the current research context.
Options Flow
Normal options activity (no specific unusual options activity data provided in research).
Earnings Intelligence
Next Earnings
Estimated late July/early August 2026 (for Q2 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Q1 2026 results saw an EPS beat but a revenue miss, indicating the market may react positively to bottom-line improvements but remains sensitive to sales targets.
Key Metrics to Watch
Competitive Position
Top Competitor
Diverse oncology players (e.g., BMS, Merck, Roche)
Market Share Trend
Gaining market share in its specific indications, driven by strong early commercialization of Revuforj and Niktimvo.
Valuation vs Peers
Likely trading at a premium to broader pharmaceutical peers due to higher growth potential, but competitive within high-growth, early-commercial biotech.
Competitive Advantages
- •Differentiated pipeline assets with novel mechanisms of action (e.g., Revuforj, axatilimab)
- •Strategic collaboration with Menarini Group for Niktimvo
- •Strong initial commercial traction validating market acceptance
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SNDX Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 data readouts (multiple programs, per guidance)
- •2026 Annual Meeting on June 10, 2026 (vote on equity plan)
Medium-Term (6-18 months)
- •Topline axatilimab Phase 2 data in Q4 2026
- •Continued ramp-up of Revuforj and Niktimvo commercial sales
- •Potential for new strategic partnerships or expanded indications
Long-Term (18+ months)
- •Advancement of pipeline candidates into later-stage clinical trials
- •Establishment as a market leader in specific oncology niches
- •Achieving sustainable profitability and positive free cash flow
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SNDX?
- ✓
Acceleration in Revuforj and Niktimvo quarter-over-quarter sales growth
- ✓
Positive clinical trial data readouts for axatilimab and other pipeline assets
- ✓
Clear and consistent improvement in gross and operating margins
Bull Case Analysis
See what could go right with Premium
Competing with SNDX
See how Syndax Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Syndax Pharmaceuticals Inc SNDX | $1.7B | 6.7 | -6.0 | $172.3M | -165.4% | 628.9% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Syndax Pharmaceuticals Inc Makes Money
Syndax Pharmaceuticals is a clinical-stage oncology company that discovers, develops, and commercializes innovative therapies for difficult-to-treat cancers. It generates revenue primarily through the direct net sales of its approved product, Revuforj, which targets specific blood cancers. Additionally, Syndax earns collaboration revenue from partners, like Menarini Group, who market its other therapies, such as Niktimvo, globally. The company heavily invests in research and development to expand its pipeline of novel cancer treatments, aiming to address unmet medical needs and capture significant market share in specialized oncology indications.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Syndax Pharmaceuticals Inc (SNDX)?
As of May 4, 2026, Syndax Pharmaceuticals Inc has a DVR Score of 6.7 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Syndax Pharmaceuticals Inc?
Syndax Pharmaceuticals Inc's market capitalization is approximately $1.7B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Syndax Pharmaceuticals Inc use?
SNDX is the ticker symbol for Syndax Pharmaceuticals Inc. The company trades on the NMS.
What is the risk level for SNDX stock?
Our analysis rates Syndax Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of SNDX?
Syndax Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of -6.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Syndax Pharmaceuticals Inc's revenue growing?
Syndax Pharmaceuticals Inc has reported revenue growth of 628.9%. The company is showing strong top-line momentum.
Is SNDX stock profitable?
Syndax Pharmaceuticals Inc has a profit margin of -165.4%. The company is currently unprofitable.
How often is the SNDX DVR analysis updated?
Our AI-powered analysis of Syndax Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 4, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SNDX (Syndax Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.